Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + azacitidine maintenance after allo-HSCT in adult T-ALL/T-LBL
ChiCTR2500114134Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Dec 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat and azacitidine in t-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: 1-year cumulative relapse rate (CIR). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
tucidinostatazacitidine
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T-lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on ChiCTR2500114134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114134.